Caixin
BUSINESS & TECH

Innovent Rejoins Race to Launch Cancer Therapy

Biomedical developer Innovent is back in the race to become the first to offer a new class of biological cancer-fighting drugs in China. Photo: VCG
Biomedical developer Innovent is back in the race to become the first to offer a new class of biological cancer-fighting drugs in China. Photo: VCG

Chinese biomedical developer Innovent Biologics Inc. has rejoined the race against foreign giants including Merck & Co. and Bristol-Myers Squibb to launch a cutting-edge cancer therapy in China.

Innovent has resubmitted its application with the China Food and Drug Administration’s Center for Drug Evaluation (CDE) to launch an immunotherapy injection to treat lymphoma in China, according to the CDE’s database.

ladingImg
You've accessed an article available only to subscribers
Try 4 weeks for $0.99
SUBSCRIBE
Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.